Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Six Months ended September 30, 2018
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company manufactures and markets generic drugs, active pharmaceutical ingredients (APIs), and differentiated formulations globally, with principal markets in India, the United States, Russia, Ukraine, and Germany.
Key Financial Metrics
Figures in millions of Indian Rupees (Rs.) unless otherwise noted. Convenience translation to U.S. dollars provided at $1.00 = Rs. 72.54.
| Metric | Six Months Ended Sep 30, 2018 | Six Months Ended Sep 30, 2017 | Three Months Ended Sep 30, 2018 | Three Months Ended Sep 30, 2017 |
|---|---|---|---|---|
| Revenues | Rs. 75,185 (U.S.$ 1,036) | Rs. 68,619 | Rs. 37,978 (U.S.$ 524) | Rs. 35,460 |
| Gross Profit | Rs. 41,625 (55.4% margin) | Rs. 35,998 (52.5% margin) | Rs. 20,897 (55.0% margin) | Rs. 18,901 (53.3% margin) |
| Profit Before Tax | Rs. 10,787 | Rs. 4,648 | Rs. 5,780 | Rs. 3,876 |
| Profit for the Period (Net Income) | Rs. 9,599 (U.S.$ 132) | Rs. 3,440 | Rs. 5,038 (U.S.$ 69) | Rs. 2,849 |
| Effective Tax Rate | 11.0% | 25.9% | 12.8% | 26.5% |
| Cash & Equivalents (Sep 30, 2018) | Rs. 3,780 (U.S.$ 52) | - | ||
| Total Debt (Short + Long Term) | Rs. 55,514 (U.S.$ 765) | - | ||
| Net Cash from Operating Activities (6mo) | Rs. 5,706 | Rs. 4,728 | - |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 10% (6-month) and 7% (quarterly) year-over-year. Growth was driven by the Global Generics segment (+9% 6-month) and PSAI segment (+11% 6-month).
- Profitability Surge: Net profit increased 179% for the six months ended September 30, 2018, and 77% for the quarter. This was primarily due to a significant reduction in the effective tax rate (from ~26% to ~11-13%) and higher operating margins.
- Segment Performance:
- Global Generics: North America revenues were flat in INR terms but declined 2-6% in absolute USD terms due to price erosion, partially offset by new product launches. Emerging Markets (Russia, etc.) saw strong growth (+26% 6-month).
- PSAI: Revenues grew due to higher sales volumes of APIs and increased orders for pharmaceutical development services.
- One-Time Gains: "Other income, net" increased significantly due to a gain of Rs. 464 million from the sale of rights to an intangible asset and the sale of the Tennessee manufacturing facility.
- Working Capital: Days Sales Outstanding (DSO) increased to 110 days from 102 days, attributed to extended credit periods for North American customers and exchange rate impacts.
Guidance, Outlook, Risks, and Contingencies
- Regulatory Matters (FDA): The company continues to address a 2015 warning letter regarding cGMP deviations at facilities in Srikakulam, Miryalaguda, and Duvvada. While the Miryalaguda API facility inspection was closed successfully, the Duvvada oncology facility received a new Form 483 in October 2018 with eight observations. The Srikakulam API facility remains under review. The FDA has withheld approval of new products from these facilities pending resolution.
- Legal Proceedings:
- Suboxone Litigation: A preliminary injunction was granted against DRL by Indivior PLC in the U.S. regarding a generic Suboxone film. DRL has appealed to the Federal Circuit, awaiting judgment.
- Antitrust Litigation: DRL is a defendant in Multi-District Litigation (MDL-2724) alleging price-fixing conspiracies involving generic drugs. The company intends to vigorously defend these claims.
- Environmental: Ongoing proceedings regarding land and water pollution in the Patancheru/Bollarum area of India. The company believes potential liabilities are not material.
- Divestiture: In October 2018, DRL entered an agreement to sell its API Hyderabad Plant 4 (PSAI segment) to Therapiva Private Limited. Assets are classified as a disposal group held for sale.
- Outlook: Management continues to focus on building a pipeline of complex generics, biosimilars, and differentiated products. R&D expenses decreased slightly due to timing of milestone payments.
Key Facts for Investor Verification
- Tax Rate Volatility: Verify the sustainability of the reduced effective tax rate (11.0% vs 25.9% prior year), which was driven by jurisdictional mix changes and the resolution of a specific tax matter.
- FDA Compliance Status: Monitor the resolution of the October 2018 Form 483 observations at the Duvvada facility and the ongoing review of the Srikakulam facility, as these impact new product approvals.
- North America Pricing: Assess the impact of price erosion in the U.S. market on the Global Generics segment, which remains the largest revenue contributor.
- Legal Exposure: Track the outcome of the Suboxone appeal and the MDL-2724 antitrust litigation, as adverse rulings could result in material liabilities.
- Divestiture Completion: Confirm the closing of the API Hyderabad Plant 4 sale and the financial impact of the disposal group.